Spexib Capsules are formulated for treatment of non-small cell lung cancer. They contain certinib as active compound with molecular formula C28H36ClN5O3S and molar mass of 558.14 g/mol. These capsules work by inhibiting anaplastic lymphoma kinase and mutated enzymes resulting in proliferation of cancerous cells. Spexib Capsules are highly appreciated for having targeted mode of action and are only consumed under prescription.
They get metabolized by CYP3A4
These capsules have elimination of half life of around 41 hours
They have protein binding ability of up to 97%
Developed and Managed by Infocom Network Private Limited.